Impact of Covid-19 on Rhinovirus Epidemic

NCT ID: NCT05348707

Last Updated: 2022-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-31

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring.

The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI).

However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinovirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre Covid 19 cohort

Infants hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020.

epidemiology

Intervention Type OTHER

To review medical records to describe diagnosis and severity of the disease.

epidemiology

Intervention Type OTHER

To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Per Covid 19 cohort year 1

Infant hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available.

epidemiology

Intervention Type OTHER

To review medical records to describe diagnosis and severity of the disease.

epidemiology

Intervention Type OTHER

To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Per Covid 19 cohort, year 2

Infants hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed.

epidemiology

Intervention Type OTHER

To review medical records to describe diagnosis and severity of the disease.

epidemiology

Intervention Type OTHER

To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

epidemiology

To review medical records to describe diagnosis and severity of the disease.

Intervention Type OTHER

epidemiology

To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medical record analysis Comparison of cohorts

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France
* Positive rhinovirus-PCR

Exclusion Criteria

* \- parent's refusal to participate
Maximum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dominique PLOIN, MD

Role: CONTACT

: 04 27 85 56 42

Jean Sebastien CASALEGNO, MD

Role: CONTACT

04 72 07 10 23

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502_2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Randomised Evaluation of COVID-19 Therapy
NCT04381936 RECRUITING PHASE3
Outpatient Use of Ivermectin in COVID-19
NCT04530474 WITHDRAWN PHASE3
Alleviation of Common Cold Symptoms
NCT06106880 COMPLETED PHASE1